Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study - Concepedia

Concepedia

Publication | Open Access

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

DOI Full Paper Access

99

Citations

18

References

2018

Year

C. Paul, C.E.M. Griffiths, P.C.M. van de Kerkhof, L. Puig, Yves Dutronc, Carsten Henneges, Martín Dossenbach, Kristin Hollister, Kristian Reich

Journal of the American Academy of Dermatology

RheumatologySuperior EfficacyAutoimmune DiseaseSystemic TreatmentImmunologyClinical TrialsPharmacotherapyMedicinePhase 3

References

	Year	Citations

Page 1

Page 1